In a recent development, the U.S. Food and Drug Administration has granted approval to Avadel Pharmaceuticals for the expanded use of their sleep disorder medication, Lumryz, for children aged 7 years and above. Lumryz, previously approved for adult patients in 2023, is now also cleared for treating pediatric individuals exhibiting symptoms of narcolepsy such as cataplexy and excessive daytime sleepiness (EDS).
Narcolepsy, a chronic neurological disorder affecting the brain's sleep-wake cycle regulation, often manifests with sudden muscle weakness (cataplexy) in around 70% of patients. Lumryz sets itself apart from Jazz Pharmaceuticals' popular drugs, Xyrem and Xywav, with its unique once-nightly dosing regimen that eliminates the need for patients to awaken in the middle of the night. This convenience factor could prove to be a significant advantage for Lumryz in the market.
Lumryz contains sodium oxybate, a central nervous system depressant that aids in enhancing deep sleep duration. With children constituting a small fraction of the current population treated with oxybate, Avadel's pediatric approval is anticipated to further boost the drug's market potential. Analysts at Jefferies predict Lumryz to achieve peak annual sales of $550 million to $1 billion, with the pediatric approval contributing an additional $50 to $100 million.
While Jazz Pharmaceuticals' Xywav and Xyrem are also indicated for narcolepsy treatment, Xywav holds an expanded FDA approval to address idiopathic hypersomnia, a rare neurological disorder characterized by excessive daytime sleepiness. Jazz reported substantial revenue from Xyrem and Xywav last year, totaling $1.27 billion and $569.7 million, respectively, further highlighting the competitive landscape in the sleep disorder treatment market.
Despite the positive news of Lumryz expanding its target patient population, the drug comes with a boxed warning regarding reduced stimulation of the central nervous system and the potential for abuse and misuse. Nevertheless, the approval of Lumryz for pediatric narcolepsy treatment marks a significant milestone for Avadel Pharmaceuticals. Following the announcement, Avadel's shares rose by 1.4% to $13.43, reflecting market optimism about the drug's potential success.
Initially expected in September, the FDA's decision on Lumryz was delayed for further review, underscoring the importance of rigorous evaluation and safety considerations in approving medications for pediatric use.